Literature DB >> 17239099

Treatment of status epilepticus in adults: guidelines of the Italian League against Epilepsy.

Fabio Minicucci1, Giancarlo Muscas, Emilio Perucca, Giuseppe Capovilla, Federico Vigevano, Paolo Tinuper.   

Abstract

Status epilepticus (SE) is a medical emergency which can lead to significant morbidity and mortality and requires prompt diagnosis and treatment. SE is differentiated into generalized or partial SE on the basis of its electro-clinical manifestations. The guidelines for the management of SE produced by the Italian League against Epilepsy also distinguish three different stages of SE (initial, established and refractory), based on time elapsed since the onset of the condition and responsiveness to previously administered drugs. Treatment should be started as soon as possible, particularly in generalized convulsive SE, and should include general support measures, drugs to suppress epileptic activity and, whenever possible, treatments aimed at relieving the underlying (causative) condition. Benzodiazepines are the first line antiepileptic agents, and i.v. lorazepam is generally preferred because it is associated with a lower risk of early relapses. If benzodiazepines fail to control seizures, i.v. phenytoin is usually indicated, though i.v. phenobarbital or i.v. valproate may also be considered. Refractory SE requires admission to an intensive care unit (ICU) to allow adequate monitoring and support of respiratory, metabolic and hemodynamic functions and cerebral electrical activity. In refractory SE, general anesthesia may be required. Propofol and thiopental represent first line agents in this setting, after careful assessment of potential risks and benefits.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17239099     DOI: 10.1111/j.1528-1167.2006.00870.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  12 in total

1.  New treatment options in status epilepticus: a critical review on intravenous levetiracetam.

Authors:  Eugen Trinka; Judith Dobesberger
Journal:  Ther Adv Neurol Disord       Date:  2009-03       Impact factor: 6.570

2.  Recent and future advances in the treatment of status epilepticus.

Authors:  Felix Rosenow; Susanne Knake
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

3.  ECoG studies of valproate, carbamazepine and halothane in frontal-lobe epilepsy induced by head injury in the rat.

Authors:  Clifford L Eastman; Derek R Verley; Jason S Fender; Nancy R Temkin; Raimondo D'Ambrosio
Journal:  Exp Neurol       Date:  2010-04-24       Impact factor: 5.330

4.  Treatment deviating from guidelines does not influence status epilepticus prognosis.

Authors:  Andrea O Rossetti; Vincent Alvarez; Jean-Marie Januel; Bernard Burnand
Journal:  J Neurol       Date:  2012-08-17       Impact factor: 4.849

5.  Nonconvulsive status epilepticus: a diagnostic and therapeutic challenge in the intensive care setting.

Authors:  Martin Holtkamp; Hartmut Meierkord
Journal:  Ther Adv Neurol Disord       Date:  2011-05       Impact factor: 6.570

Review 6.  Treatment of Generalized Convulsive Status Epilepticus in Pediatric Patients.

Authors:  Elizabeth L Alford; James W Wheless; Stephanie J Phelps
Journal:  J Pediatr Pharmacol Ther       Date:  2015 Jul-Aug

7.  Impact of treatment on the short-term prognosis of status epilepticus in two population-based cohorts.

Authors:  Luca Vignatelli; Rita Rinaldi; Elisa Baldin; Paolo Tinuper; Roberto Michelucci; Massimo Galeotti; Piero de Carolis; Roberto D'Alessandro
Journal:  J Neurol       Date:  2008-01-23       Impact factor: 4.849

Review 8.  Diagnostic work-up and therapeutic options in management of pediatric status epilepticus.

Authors:  Mario Mastrangelo; Andrea Celato
Journal:  World J Pediatr       Date:  2012-05-10       Impact factor: 2.764

9.  Immediate Epileptogenesis after Kainate-Induced Status Epilepticus in C57BL/6J Mice: Evidence from Long Term Continuous Video-EEG Telemetry.

Authors:  Sreekanth Puttachary; Shaunik Sharma; Karen Tse; Edward Beamer; Abby Sexton; Joseph Crutison; Thimmasettappa Thippeswamy
Journal:  PLoS One       Date:  2015-07-10       Impact factor: 3.240

10.  Clinical Performance Measures for Neurocritical Care: A Statement for Healthcare Professionals from the Neurocritical Care Society.

Authors:  Sarah Livesay; Herbert Fried; David Gagnon; Navaz Karanja; Abhijit Lele; Asma Moheet; Casey Olm-Shipman; Fabio Taccone; David Tirschwell; Wendy Wright; J Claude Hemphill Iii
Journal:  Neurocrit Care       Date:  2020-02       Impact factor: 3.210

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.